144 related articles for article (PubMed ID: 24423298)
1. Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes.
Thankamony A; Tossavainen PH; Sleigh A; Acerini C; Elleri D; Dalton RN; Jackson NC; Umpleby AM; Williams RM; Dunger DB
J Clin Endocrinol Metab; 2014 Feb; 99(2):639-47. PubMed ID: 24423298
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
[TBL] [Abstract][Full Text] [Related]
3. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
[TBL] [Abstract][Full Text] [Related]
4. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
5. Substrate Metabolism and Insulin Sensitivity During Fasting in Obese Human Subjects: Impact of GH Blockade.
Pedersen MH; Svart MV; Lebeck J; Bidlingmaier M; Stødkilde-Jørgensen H; Pedersen SB; Møller N; Jessen N; Jørgensen JOL
J Clin Endocrinol Metab; 2017 Apr; 102(4):1340-1349. PubMed ID: 28324055
[TBL] [Abstract][Full Text] [Related]
6. Short-term, low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency.
Yuen KC; Roberts CT; Frystyk J; Rooney WD; Pollaro JR; Klopfenstein BJ; Purnell JQ
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1862-9. PubMed ID: 25013996
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes.
Simpson HL; Jackson NC; Shojaee-Moradie F; Jones RH; Russell-Jones DL; Sönksen PH; Dunger DB; Umpleby AM
J Clin Endocrinol Metab; 2004 Jan; 89(1):425-32. PubMed ID: 14715881
[TBL] [Abstract][Full Text] [Related]
8. Effects of growth hormone and free fatty acids on insulin sensitivity in patients with type 1 diabetes.
Salgin B; Marcovecchio ML; Williams RM; Jackson SJ; Bluck LJ; Humphreys SM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2009 Sep; 94(9):3297-305. PubMed ID: 19567515
[TBL] [Abstract][Full Text] [Related]
9. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
[TBL] [Abstract][Full Text] [Related]
11. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.
Moller L; Norrelund H; Jessen N; Flyvbjerg A; Pedersen SB; Gaylinn BD; Liu J; Thorner MO; Moller N; Lunde Jorgensen JO
J Clin Endocrinol Metab; 2009 Nov; 94(11):4524-32. PubMed ID: 19820031
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
Bajpeyi S; Pasarica M; Conley KE; Newcomer BR; Jubrias SA; Gamboa C; Murray K; Sereda O; Sparks LM; Smith SR
Metabolism; 2017 Apr; 69():24-32. PubMed ID: 28285649
[TBL] [Abstract][Full Text] [Related]
13. The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes.
Bernroider E; Brehm A; Krssak M; Anderwald C; Trajanoski Z; Cline G; Shulman GI; Roden M
J Clin Endocrinol Metab; 2005 Oct; 90(10):5559-65. PubMed ID: 15998784
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults.
Krusenstjerna-Hafstrøm T; Clasen BF; Møller N; Jessen N; Pedersen SB; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2011 Aug; 96(8):2548-57. PubMed ID: 21613350
[TBL] [Abstract][Full Text] [Related]
15. Glucose flux is normalized by compensatory hyperinsulinaemia in growth hormone-induced insulin resistance in healthy subjects, while skeletal muscle protein synthesis remains unchanged.
Nygren J; Thorell A; Brismar K; Essén P; Wernerman J; McNurlan MA; Garlick PJ; Ljungqvist O
Clin Sci (Lond); 2002 Apr; 102(4):457-64. PubMed ID: 11914108
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.
Muller AF; Janssen JA; Hofland LJ; Lamberts SW; Bidlingmaier M; Strasburger CJ; van der Lely AJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):590-3. PubMed ID: 11158013
[TBL] [Abstract][Full Text] [Related]
17. GH receptor blocker administration and muscle-tendon collagen synthesis in humans.
Nielsen RH; Doessing S; Goto K; Holm L; Reitelseder S; Agergaard J; Schjerling P; Flyvberg A; Kjaer M
Growth Horm IGF Res; 2011 Jun; 21(3):140-5. PubMed ID: 21498100
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes.
Perseghin G; Lattuada G; Danna M; Sereni LP; Maffi P; De Cobelli F; Battezzati A; Secchi A; Del Maschio A; Luzi L
Am J Physiol Endocrinol Metab; 2003 Dec; 285(6):E1174-81. PubMed ID: 12933352
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans.
Bachmann OP; Dahl DB; Brechtel K; Machann J; Haap M; Maier T; Loviscach M; Stumvoll M; Claussen CD; Schick F; Häring HU; Jacob S
Diabetes; 2001 Nov; 50(11):2579-84. PubMed ID: 11679437
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade.
Nielsen C; Gormsen LC; Jessen N; Pedersen SB; Møller N; Lund S; Jørgensen JO
J Clin Endocrinol Metab; 2008 Jul; 93(7):2842-50. PubMed ID: 18460563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
